Postoperative adjuvant interferon therapy for hepatitis B virus infected hepatocellular carcinoma: a Meta-analysis
10.3760/cma.j.issn.1007-8118.2014.02.001
- VernacularTitle:干扰素辅助治疗乙肝相关性肝癌术后患者的Meta分析
- Author:
Jianbo XU
;
Fuzhen QI
;
Gang XU
;
Guofeng CHEN
;
Jianhuai ZHANG
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
Interferon;
Surgery;
Recurrence rate;
Overall survival rate
- From:
Chinese Journal of Hepatobiliary Surgery
2014;20(2):81-85
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy of postoperative adjuvant interferon (IFN) therapy on patients with hepatitis B virus (HBV) related hepatocellular carcinoma (HCC).Methods An electronic search for articles published from January 2000 to January 2013 was conducted to identify English language comparative studies evaluating IFN therapy on recurrence and survival after surgical treatment of HCC.Results A total of five trials consisting of 694 patients were included in the Meta-analysis.The estimated odds ratios (OR) for the 1-,2-,3-,and 5-year overall survival rates of HBV-related HCC were 3.37 (95％CI:1.18-6.27,P=0.000),2.36 (95％ CI:1.45-3.83,P=0.001),1.81 (95％ CI:1.21-2.72,P=0.004),and 1.93 (95％ CI:1.35-2.75,P=0.000),respectively.The OR for the 1-,2-,3-,and 5-year recurrence rates were 0.63 (95％ CI:0.44-0.91,P=0.014),0.84 (95％ CI:0.60-1.18,P=0.322),0.88 (95％ CI:0.63-1.22,P=0.431),and 0.78 (95％ CI:0.56-1.07,P=0.120),respectively.Conclusion This Meta-analysis shows that IFN therapy had a significant clinical effect in improving overall survival rates but not in decreasing recurrence rates of HBV infected HCC patients postoperatively.
